Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, January 27, 2023
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
[ Fri, Jan 27th 2023
] - WOPRAI
Roanna Ruiz Maintained (AVIR) at Hold with Decreased Target to $6 on, Jan 27th, 2023
Roanna Ruiz of SVB Leerink, Maintained "Atea Pharmaceuticals, Inc." (AVIR) at Hold with Decreased Target from $8 to $6 on, Jan 27th, 2023.
Roanna has made no other calls on AVIR in the last 4 months.
There is 1 other peer that has a rating on AVIR. Out of the 1 peers that are also analyzing AVIR, 0 agree with Roanna's Rating of Hold.
This is the rating of the analyst that currently disagrees with Roanna
- Matthew Harrison of "Morgan Stanley" Maintained at Sell with Decreased Target to $4 on, Tuesday, January 24th, 2023
